• 52,739+ CME Conference Registrations Sold
  • 158,218+ Medical Conferences
  • 285 Specialties
  • 11,420 Organizers
  • 157,118 Speakers
  • 159 Countries
  • 4,801 Cities

New Clinical Perspectives in the Management of Myelofibrosis is organized by i3 Health.

Release Date: Oct 1, 2019
Expiration Date: Sep 30, 2020

Target Audience:
Hematology/oncology physicians, oncology advanced practitioners, and other health care professionals involved in the management of patients with myelofibrosis.

Accreditation:
Physicians:

i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. 

Physician Assistants:
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Description:
Myelofibrosis is a rare type of myeloproliferative neoplasm-a heterogenous group of hematopoietic disorders-that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transplant, the only potentially curative treatment option available. Due to the dearth of effective treatment options, therapeutic goals are focused on slowing progression and maintaining quality of life. Median overall survival varies across risk groups, ranging from 15.4 years for patients with low-risk disease to only 1.3 years for those with high-risk disease. Furthermore, up to 20% of myelofibrosis cases transform to acute myeloid leukemia, where the 5-year overall survival rate is only 27%.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess predictive and prognostic markers that can rationally inform personalized care planning in myelofibrosis.
• Apply emerging data in therapeutic strategies to improve survival and quality of life in patients with myelofibrosis.
• Discuss the implications that research advances in myelofibrosis may have for future clinical practice.

Intended Audience

Oncology, Haematology, Haematopathology

Activity Payment Details

Activity Fee : Free
Interested

Rate this CME (Min 1 - Max 5)

Duration:
Fee and expenses:
CME credits:
Program contents:
Networking:
Write Your Review

Reviews Given by Professionals

No Reviews available. Be the first to write a review.

Privacy Policy

Read eMedEvents Privacy Policy

Help

973-928-8085

Convert
Live to Virtual Conference

Market your online event to Million plus Healthcare professionals.

Recommended